Skip to main content
Tony (Vanho) Ho, MD, Oncology, Portland, OR, Legacy Emanuel Medical Center

TonyV(Vanho)HoMD

Oncology Portland, OR

Hematologic Oncology

Physician

Are you Dr. Ho?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 35 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Tony (Vanho) Ho, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon and Washington. He is affiliated with Legacy Emanuel Medical Center and Legacy Good Samaritan Medical Center.

Education & Training

  • University of Utah Health
    University of Utah HealthFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Legacy Health/Emanuel Medical Center
    Legacy Health/Emanuel Medical CenterResidency, Internal Medicine, 1996 - 1999
  • University of Utah School of Medicine
    University of Utah School of MedicineClass of 1996

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2002 - 2025
  • OR State Medical License
    OR State Medical License 2002 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Press Mentions

  • iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of Directors
    iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of DirectorsMay 3rd, 2021
  • iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of Directors
    iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of DirectorsMay 3rd, 2021
  • CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel in Vivo Delivery Technologies
    CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel in Vivo Delivery TechnologiesJanuary 22nd, 2019

Hospital Affiliations